Karen Khan
Columbia University Irving Medical Center(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Histone Deacetylase Inhibitors Research, Multiple and Secondary Primary Cancers, Cutaneous lymphoproliferative disorders research
Most-Cited Works
- → A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma(2017)133 cited
- → Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study(2019)127 cited
- → High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy(2016)49 cited
- → A Case of Bing–Neel Syndrome Successfully Treated with Ibrutinib(2018)22 cited
- → Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)(2018)17 cited
- → A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)(2017)10 cited
- → PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses(2016)7 cited
- → CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30‐POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202)(2019)7 cited
- → Rate of complete metabolic responses to immune checkpoint inhibitors in extremely heavily pre-treated patients with classical Hodgkin’s lymphoma and immunoepigenetic priming.(2016)5 cited
- → Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma(2020)4 cited